Concomitant disseminated histoplasmosis and disseminated tuberculosis after tumor necrosis factor inhibitor treatment: a case report

被引:8
作者
Munoz-Oca, Juan E. [1 ]
Morales, Martha L. Villarreal [2 ]
Nieves-Rodriguez, Aracelis [3 ]
Martinez-Bonilla, Lemuel [4 ]
机构
[1] Manati Med Ctr, Family Med Residency Program, POB 1142, Manati, PR 00674 USA
[2] Manati Med Ctr, Dept Med Educ, POB 1142, Manati, PR 00674 USA
[3] Manati Med Ctr, Dept Family Med, POB 1142, Manati, PR 00674 USA
[4] Manati Med Ctr, Dept Internal Med Infect Dis, POB 1142, Manati, PR 00674 USA
关键词
Histoplasmosis; Tuberculosis; Co-infection; TNF-alpha inhibitors; Adalimumab; Case report; PHARMACOKINETICS;
D O I
10.1186/s12879-016-2097-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Tumor necrosis factor antagonist inhibitors have transformed the approach to patients with severe autoimmune conditions, such as rheumatoid arthritis. Although the therapy can be highly effective, TNF-alpha inhibitors are associated with an increased risk of opportunistic infections. Case presentation: Here, we report a case of concomitant disseminated histoplasmosis and tuberculosis in a 65-year-old female with rheumatoid arthritis treated with TNF-alpha inhibitor. Both conditions can be found in disseminated form in immunosuppressed hosts, but co-infection is rare with only a few cases having been reported, to our knowledge, all in HIV patients. Conclusions: This case posed a considerable challenge for diagnosis and treatment due to the unusual disseminated co-infection, the overlapping symptoms, and the interactions between medications.
引用
收藏
页数:4
相关论文
共 12 条
  • [1] Tuberculosis and Histoplasmosis Co-Infection in AIDS Patients
    Agudelo, Carlos A.
    Restrepo, Carlos A.
    Molina, Diego A.
    Tobon, Angela M.
    Kauffman, Carol A.
    Murillo, Carolina
    Restrepo, Angela
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2012, 87 (06) : 1094 - 1098
  • [2] [Anonymous], 2015, Global Tuberculosis Report
  • [3] Anstead GM, 2009, CLIN MYCOLOGY, P355
  • [4] Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs
    Benedetti, MS
    [J]. PHARMACOLOGICAL RESEARCH, 1995, 32 (04) : 177 - 187
  • [5] Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial
    Conde, Marcus B.
    Efron, Anne
    Laredo, Carla
    Muzy De Souza, Gilvan R.
    Graca, Nadja P.
    Cezar, Michelle C.
    Ram, Malathi
    Chaudhary, Mohammad A.
    Bishai, William R.
    Kritski, Afranio L.
    Chaisson, Richard E.
    [J]. LANCET, 2009, 373 (9670) : 1183 - 1189
  • [6] Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk -: A multicenter active-surveillance report
    Gómez-Reino, JJ
    Carmona, L
    Valverde, VR
    Mola, EM
    Montero, MD
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (08): : 2122 - 2127
  • [7] Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients
    Jaruratanasirikul, S
    Sriwiriyajan, S
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (02) : 155 - 158
  • [8] Histoplasmosis: a clinical and laboratory update
    Kauffman, Carol A.
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2007, 20 (01) : 115 - +
  • [9] Lanzafame Massimiliano, 2016, J Clin Tuberc Other Mycobact Dis, V3, P6, DOI 10.1016/j.jctube.2016.03.002
  • [10] QuantiFERON TB Gold Testing for Tuberculosis Screening in an Inflammatory Bowel Disease Cohort in the United States
    Qumseya, Bashar J.
    Ananthakrishnan, Ashwin N.
    Skaros, Sue
    Bonner, Michael
    Issa, Mazen
    Zadvornova, Yelena
    Naik, Amar
    Perera, Lilani
    Binion, David G.
    [J]. INFLAMMATORY BOWEL DISEASES, 2011, 17 (01) : 77 - 83